CliffBio
small molecule

APREMILAST

APREMILAST

Loss of exclusivity—loss of exclusivity
CompanyShilpa Medicare →See this company's full patent-cliff portfolio

Drug detail

Brand nameAPREMILAST
Active ingredientAPREMILAST
Strength20MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalApril 2023
Marketing statusRX

More from Shilpa Medicare

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

APREMILAST patent cliff — loss of exclusivity — | CliffBio